erenumab

04/01/2023 - "Erenumab had remarkable efficacy in the short and long-term treatment of episodic and chronic migraine, notably the patients with difficult-to-treat migraine headaches."
12/01/2021 - "Erenumab was effective in migraine patients who were highly refractory to previous prophylactics. "
11/01/2022 - "In all eight included trials, we found that erenumab (28, 70, and 140 mg) is very effective and has a significantly greater reduction in baseline monthly migraine days (28 mg: mean difference [MD] = -1.1, 95% confidence interval [CI]: -2.0 to -0.2, p = 0.020; 70 mg: MD = -1.4, 95% CI: -1.8 to -1.1, p < 0.001, I2  = 26%; 140 mg: MD = -1.8, 95% CI: -2.1 to -1.4, p < 0.001, I2  = 0%) than placebo at week 12, especially with 140 mg. "
07/01/2022 - "Erenumab has been proven to be significantly effective in patients with episodic migraines when used at doses of 70 or 140 mg. "
01/01/2022 - "In two 24-week migraine prevention studies in Japan, erenumab was associated with significantly greater reductions in migraine frequency versus placebo over Weeks 13-24 (primary endpoint). "

01/01/2022 - "The efficacy of erenumab in our case presumes that CGRP might also be an important mediator in facilitating primary headache associated with sexual activity."
11/17/2020 - "Furthermore, when responders (n = 9) and nonresponders (n = 8) of the respective same headache state were compared, we found a significant reduction of hypothalamic activation after the administration of erenumab in responders only (t = 4.78; contrast estimate 29.79 [90% confidence interval 19.53-40.05]). "
07/23/2021 - "In the acute headache medication users at baseline, the change in monthly acute HMD at Month 3 compared with pre-DBTP was 3.4, 5.5, and 6.5 for placebo, erenumab 70 mg and 140 mg, respectively for the CM study. "
07/23/2021 - "For acute headache medication users, the change in mean monthly acute HMD over Months 4, 5 and 6 compared with the pre-DBTP was 1.5, 2.5, and 3.0 for placebo, erenumab 70 mg and 140 mg, respectively for the EM study. "
06/01/2021 - "The study aim was to characterize the real-world treatment profiles, clinical outcomes, and healthcare resource utilization of patients prescribed erenumab from select major US headache centers. "

05/12/2023 - "In particular, erenumab is the mAb that has shown good therapeutic efficacy in reducing pain intensity and having high tolerability. "
06/01/2021 - "This study provides Class IV evidence that erenumab increases the probability of improved pain control in patients with medication-resistant TN."
12/14/2022 - "The objective of this study was to determine if response to erenumab is associated with alterations in brain functional connectivity and pain-induced brain activations. "
01/01/2023 - "Erenumab response is associated with higher T2* in the periaqueductal gray and anterior cingulate cortex, regions that participate in pain processing and modulation. "
12/14/2022 - "Compared to erenumab non-responders, erenumab responders had post-treatment differences in 1) network functional connectivity amongst pain-processing regions, including higher global efficiency, clustering coefficient, node degree, regional efficiency, and modularity, 2) region-to-region functional connectivity between several regions including temporal pole, supramarginal gyrus, and hypothalamus, and 3) pain-induced activations in the middle cingulate, posterior cingulate, and periaqueductal gray matter. "

10/01/2021 - "The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting, up to 1 year. "
12/14/2021 - "Medication overuse headache showed a lower probability of therapy success with erenumab (odds ratio: 0.126, p = 0.039). "
02/01/2022 - "To determine whether erenumab is effective and safe in refractory chronic migraine with medication overuse headache. "
02/01/2022 - "In this prospective, multicentric, real-life study, chronic migraine with medication overuse headache patients who received erenumab were recruited. "
01/01/2022 - "Randomized clinical trials proved the superiority of erenumab to placebo in a strictly selected population, while real-world studies confirmed treatment efficacy in more severe forms of disease - most patients suffered from chronic migraine with medication overuse headache, had prior treatment failures, and long disease duration. "

03/01/2022 - "Erenumab Safe, Effective for Patients With Migraine With Aura."
01/01/2022 - "To assess the efficacy and safety profiles of erenumab in patients with migraine with aura. "
10/01/2021 - "Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study."
09/01/2022 - "To assess efficacy of erenumab, galcanezumab, and fremanezumab in reducing headache in patients with chronic migraine complicated by medication overuse headache. "